📊 Top Mid-sized Pharma by cash available 👇

As financing becomes more difficult to obtain and macroeconomic signals create more uncertainties, I wanted to highlight with this graph public mid-sized pharma companies that have been able to secure a high level of cash to finance their R&D operations.

This data reflects financial reality as of 3/31/2025 and is coming from quarterly financial communications of these companies.